A Phase 3 interventional study of Aripiprazole (Abilify®) IM Depot Injection in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 124 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-05-07.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 19th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2011, is one of 34 in phase 3, and was the 69th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 17th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 50 in phase 3, and was the 42nd registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
Nonadherence to antipsychotic medications remains a frequent cause of relapse among patients with schizophrenia, increasing hospitalization rates, hospitalization days, and hospitalization costs. Among hospitalized adults, schizophrenia is the fourth most commonly diagnosed illness and has the seventh longest mean duration of hospital stay in the US. Frequent relapses and hospitalization can affect quality of life in these patients. Long-acting injections (intramuscular depot) antipsychotic medication is a means to treatment adherence and increased quality of life for patients with schizophrenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole IM depot injection 300 mg or 400 mg.
Drug: Aripiprazole (Abilify®) IM Depot Injection
400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg. Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013.
Also known as: ABILIFY®
Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).
The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥ inpatient psychiatric hospitalizations) between the retrospective period months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot. Open-label Aripiprazole IM Depot Treatment Phase 3-month Completer sample comprised of all participants who entered open-label aripiprazole IM depot treatment Phase and completed at least 3 months of treatment. This sample was used for the primary endpoint analysis (N=336).
Time frame: Retrospective period Months 4-6; Prospective period Months 4-6
Change From Baseline in PANSS (Positive and Negative Syndrome Scale) Total Score.
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The PANSS total score ranges from 30 to 210.
Time frame: Baseline to Week 24
Change From Baseline in PANSS Positive Subscale Score.
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity suspiciousness/ persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Week 24
Change From Baseline in PANSS Negative Subscale Score.
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 negative symptom constructs are blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
Time frame: Baseline to Week 24
Change From Baseline in Clinical Global Impression-Severity Score (CGI-S).
The severity of illness for each participant were rated using the CGI-S scale. To assess CGI-S, study physician were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
Time frame: Baseline to Week 24
Mean Clinical Global Impression-Improvement Score (CGI-I) by Week.
The efficacy of trial medication was rated for each participant using the CGI-I scale. The study physician would rate the participants total improvement whether or not it was entirely due to drug treatment. All responses were compared to the participants condition at Baseline of the appropriate phase. The CGI-I during Phase B were assessed relative to the participants condition at the Phase B Baseline visit. Response choices included: 0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.
Time frame: Week 4, 12 and 24
This study assessed hospitalization rates in adults with schizophrenia treated prospectively for 6 months with aripiprazole intramuscular depot compared with 6 month retrospective treatment with oral antipsychotics. The study comprised 3 phases: Tolerability/Cross-titration (Phase A), Open-label Aripiprazole (Phase B), Extension (Phase C).
| Milestone | Tolerability/Cross-titration Phase (Phase A) | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | Extension Phase (Phase C) |
|---|---|---|---|
| Started | 325 | 0 | 0 |
| Completed | 265 | 0 | 0 |
| Not completed | 60 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Withdrew: Adverse event | 16 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 5 | 0 | 0 |
| Withdrew: Physician decision | 8 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 0 | 0 |
| Milestone | Tolerability/Cross-titration Phase (Phase A) | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | Extension Phase (Phase C) |
|---|---|---|---|
| Started | 0 | 433 | 0 |
| Completed | 0 | 293 | 0 |
| Not completed | 0 | 140 | 0 |
| Withdrew: Lost to follow-up | 0 | 33 | 0 |
| Withdrew: Adverse event | 0 | 37 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 11 | 0 |
| Withdrew: Physician decision | 0 | 5 | 0 |
| Withdrew: Withdrawal by subject | 0 | 41 | 0 |
| Withdrew: Protocol deviation | 0 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 10 | 0 |
| Milestone | Tolerability/Cross-titration Phase (Phase A) | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | Extension Phase (Phase C) |
|---|---|---|---|
| Started | 0 | 0 | 192 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 192 |
| Withdrew: Lost to follow-up | 0 | 0 | 17 |
| Withdrew: Adverse event | 0 | 0 | 10 |
| Withdrew: Sponsor discontinued trial | 0 | 0 | 7 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 144 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 13 |
The comparison of inpatient psychiatric hospitalization rates (proportion of patients with ≥ inpatient psychiatric hospitalizations) between the retrospective period months 4-6 (Weeks-12 to -24) while on oral standard of care antipsychotic treatment and the prospective period Phase B months 4-6 (Weeks 12 to 24) after the switch to aripiprazole IM depot. Open-label Aripiprazole IM Depot Treatment Phase 3-month Completer sample comprised of all participants who entered open-label aripiprazole IM depot treatment Phase and completed at least 3 months of treatment. This sample was used for the primary endpoint analysis (N=336).
| participants | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Retrospective period | 91 ± 0.6 |
| Prospective period | 9 ± 0.2 |
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The PANSS total score ranges from 30 to 210.
| Units on a scale | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Week 4 (N= 390) | -7.9 ± 14.0 |
| Week 12 (N= 410) | -8.4 ± 15.6 |
| Week 24 (N= 410) | -8.4 ± 17.7 |
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity suspiciousness/ persecution, and hostility. The PANSS Positive Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Week 4 (N= 390) | -2.7 ± 4.4 |
| Week 12 (N= 410) | -2.9 ± 4.9 |
| Week 24 (N= 410) | -3.0 ± 5.4 |
The PANSS consists of three subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale are as follows: 7 Positive subscale symptom constructs, 7 Negative subscale symptom constructs and 16 General Psychopathology subscale symptom constructs. The 7 negative symptom constructs are blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).
| Units on a scale | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Week 4 | -1.7 ± 4.6 |
| Week 12 | -1.6 ± 5.1 |
| Week 24 | -1.6 ± 5.8 |
The severity of illness for each participant were rated using the CGI-S scale. To assess CGI-S, study physician were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients.
| Units on a scale | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Week 4 (N= 391) | -0.3 ± 0.8 |
| Week 12 (N= 410) | -0.4 ± 0.9 |
| Week 24 (N= 410) | -0.5 ± 1.0 |
The efficacy of trial medication was rated for each participant using the CGI-I scale. The study physician would rate the participants total improvement whether or not it was entirely due to drug treatment. All responses were compared to the participants condition at Baseline of the appropriate phase. The CGI-I during Phase B were assessed relative to the participants condition at the Phase B Baseline visit. Response choices included: 0 = not assessed; 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.
| Units on a scale | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Week 4 (N= 283) | 2.9 ± 0.9 |
| Week 12 (N= 293) | 2.7 ± 1.0 |
| Week 24 (N= 293) | 2.5 ± 1.0 |
Collected over Adverse events were monitored from ICF signed until Follow-up 30 (± 3) days after last visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | — | 61/431 (14.2%) | 60/431 (13.9%) |
| Extension Phase (Phase C) | — | 19/192 (9.9%) | 24/192 (12.5%) |
| Event | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | Extension Phase (Phase C) |
|---|---|---|
| Schizophrenia, paranoid typePsychiatric disorders | 14/431 | 3/192 |
| SchizophreniaPsychiatric disorders | 11/431 | 6/192 |
| Psychotic disorderPsychiatric disorders | 8/431 | 3/192 |
| Suicidal ideationPsychiatric disorders | 6/431 | 1/192 |
| ConvulsionNervous system disorders | 4/431 | 1/192 |
| Suicide attemptPsychiatric disorders | 3/431 | 1/192 |
| Angina pectorisCardiac disorders | 0/431 | 1/192 |
| Cardio-respiratory arrestCardiac disorders | 0/431 | 1/192 |
| Hepatitis acuteHepatobiliary disorders | 0/431 | 1/192 |
| Type 2 diabetis mellitusMetabolism and nutrition disorders | 1/431 | 1/192 |
| Event | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) | Extension Phase (Phase C) |
|---|---|---|
| InsomniaPsychiatric disorders | 29/431 | 6/192 |
| AkathisiaNervous system disorders | 27/431 | 9/192 |
| Weight increasedInvestigations | 10/431 | 11/192 |
| Age, Continuous(Years) | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Mean | 42.1 ± 12.0 |
| Sex: Female, Male(Participants) | Open-label Aripiprazole IM Depot Treatment Phase (Phase B) |
|---|---|
| Female | 132 |
| Male | 301 |
Showing the first 100 of 124 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2011, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →